The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

Boutry C.Hastie A.Diez-Domingo J.Tinoco J.C.CHONG-JEN YUAndrews C.Beytout J.Caso C.Cheng H.-S.Cheong H.J.Choo E.J.Curiac D.Di Paolo E.Dionne M.Eckermann T.Esen M.Ferguson M.Ghesquiere W.Hwang S.-J.Avelino-Silva T.J.Kosina P.Liu C.-S.Markkula J.Moeckesch B.Murta de Oliveira C.Park D.W.Pauksens K.Pirrotta P.Plassmann G.Pretswell C.Rombo L.Salaun B.Sanmartin Berglund J.Schenkenberger I.Schwarz T.Shi M.Ukkonen B.Zahaf T.Zerbini C.Schuind A.Cunningham A.L.Zoster-049 Study Group2022-06-272022-06-2720221537-6591https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116820049&doi=10.1093%2fcid%2fciab629&partnerID=40&md5=b31df9a8baffb248e1dc90ded295f3c1https://scholars.lib.ntu.edu.tw/handle/123456789/613970[SDGs]SDG3The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70journal article10.1093/cid/ciab629342832132-s2.0-85116820049